# Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

> **NCT01098981** · PHASE3 · TERMINATED · sponsor: **Cerevast Therapeutics, Inc.** · enrollment: 675 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DEVICE:** Transcranial ultrasound as an adjunctive therapy to tPA
- **DRUG:** Standard of care tPA therapy for acute ischemic stroke

## Key facts

- **NCT ID:** NCT01098981
- **Lead sponsor:** Cerevast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2015-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098981, "Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01098981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*